Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claus Garbe

Showing results (311-320 of 501) with videos related to

Pageof 51
Sort By:
Cancer Immunology, Immunotherapy : CII|September 5, 2019
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patientsBenjamin Weide, Thomas Eigentler, Chiara Catania, et al.
Pigment Cell & Melanoma Research|August 20, 2010
Meeting report from the Third Global Workshop on MelanomaSanjiv S Agarwala, Alessandra di Pietro, Keith T Flaherty, et al.
Cancer Immunology, Immunotherapy : CII|October 28, 2020
Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitorsJohanna Winter, Max M Lenders, Maximilian Gassenmaier, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 1, 2012
[Actinic keratoses]Eggert Stockfleth, Dorothea Terhorst, Axel Hauschild, et al.
European Journal of Cancer Care|August 21, 2018
Fear of cancer progression in patients with stage IA malignant melanomaTobias Wagner, Matthias Augustin, Christine Blome, et al.
European Journal of Cancer (Oxford, England : 1990)|August 11, 2015
Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guidelineCeleste Lebbe, Jürgen C Becker, Jean-Jacques Grob, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 23, 2024
Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapyFrancisco Meraz-Torres, Heike Niessner, Sarah Plöger, et al.
European Journal of Cancer (Oxford, England : 1990)|September 15, 2012
Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) studyJean Jacques Grob, Thomas Jouary, Brigitte Dréno, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 28, 2006
[Brief guidelines: malignant melanoma of the skin]Claus Garbe, Axel Hauschild, Matthias Volkenandt, et al.
Frontiers in Oncology|August 28, 2025
Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and <i>BRAF V600</i> mutationJulia Forschner, Julia Huynh, Christopher Schroeder, et al.
Pageof 51

Showing results (311-320 of 501) with videos related to

Sort By:
Pageof 51
Cancer Immunology, Immunotherapy : CII|September 5, 2019
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patientsBenjamin Weide, Thomas Eigentler, Chiara Catania, et al.
Pigment Cell & Melanoma Research|August 20, 2010
Meeting report from the Third Global Workshop on MelanomaSanjiv S Agarwala, Alessandra di Pietro, Keith T Flaherty, et al.
Cancer Immunology, Immunotherapy : CII|October 28, 2020
Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitorsJohanna Winter, Max M Lenders, Maximilian Gassenmaier, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 1, 2012
[Actinic keratoses]Eggert Stockfleth, Dorothea Terhorst, Axel Hauschild, et al.
European Journal of Cancer Care|August 21, 2018
Fear of cancer progression in patients with stage IA malignant melanomaTobias Wagner, Matthias Augustin, Christine Blome, et al.
European Journal of Cancer (Oxford, England : 1990)|August 11, 2015
Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guidelineCeleste Lebbe, Jürgen C Becker, Jean-Jacques Grob, et al.
Journal of Experimental & Clinical Cancer Research : CR|January 23, 2024
Augmenting MEK inhibitor efficacy in BRAF wild-type melanoma: synergistic effects of disulfiram combination therapyFrancisco Meraz-Torres, Heike Niessner, Sarah Plöger, et al.
European Journal of Cancer (Oxford, England : 1990)|September 15, 2012
Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) studyJean Jacques Grob, Thomas Jouary, Brigitte Dréno, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|April 28, 2006
[Brief guidelines: malignant melanoma of the skin]Claus Garbe, Axel Hauschild, Matthias Volkenandt, et al.
Frontiers in Oncology|August 28, 2025
Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and <i>BRAF V600</i> mutationJulia Forschner, Julia Huynh, Christopher Schroeder, et al.
Pageof 51